AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research

IGC Pharma Inc IGC recently entered into a Master Cooperation Agreement with the University of Los Andes, focusing on integrating generative AI solutions into various aspects of drug development and clinical trials. 

This collaboration aims to enhance the efficiency of clinical trials, particularly for IGC Pharma’s leading drug, IGC-AD1, which is currently in Phase 2 trials for treating agitation related to Alzheimer's disease symptoms.

Advancing Alzheimer’s Treatment with AI and THC

A significant aspect of this partnership is the improvement of early detection methods for Alzheimer’s disease. With a notable percentage of Alzheimer’s patients not receiving formal diagnoses, the integration of AI algorithms into the evaluation process is expected to minimize false negatives in early diagnosis, thereby improving treatment outcomes.

Furthermore, this agreement will also focus on refining drug interaction analysis. By leveraging AI algorithms, there will be a more effective methodology for analyzing drug interactions, including those involving IGC-AD1, a THC-based drug formulation for treating Alzheimer ‘s-related agitation.

CEO's Perspective

Ram Mukunda, CEO of IGC Pharma expressed enthusiasm about the partnership, envisioning transformative applications of AI in treating Alzheimer’s and other chronic illnesses. "As we execute our strategic initiatives and position IGC Pharma at the forefront of AI adoption, we expect to gain a distinct competitive advantage as we streamline clinical trial efficiencies, enhance early detection of Alzheimer's, improve methodologies for the analysis of drug interaction, and improve the treatment experience for patients, should our AI algorithms prove successful," Mukunda said.

IGC Pharma’s Efforts in Drug Development

IGC Pharma is actively pursuing the development of five drug assets targeting Alzheimer’s disease agitation, all at various stages of clinical trials and development. This includes IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3.

Global Collaboration

This partnership not only elevates IGC Pharma’s research capabilities but also highlights the importance of Latin American institutions in pioneering global healthcare advancements, particularly in the realm of AI-driven drug development.

Photo: Courtesy of geralt, lindsayfox Pixabay

Did you miss the first wave of cannabis investments? Don't make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth. Join Benzinga PotProfits. Benefit from Michael Berger's sharp analysis, revealing top cannabis stock opportunities and timely updates. Experience the potential of 10%+ returns in just 90 days. Our 4.5-star Marketfy rating speaks volumes. Secure your position in this booming sector with a 30-day money-back guarantee. The time to invest is now, before everyone else realizes it. Secure your profits with Benzinga. Click here now to learn more.